Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 4
1967 13
1968 25
1969 26
1970 35
1971 49
1972 43
1973 46
1974 39
1975 28
1976 69
1977 64
1978 74
1979 80
1980 160
1981 193
1982 202
1983 269
1984 324
1985 388
1986 494
1987 604
1988 625
1989 685
1990 809
1991 819
1992 887
1993 1033
1994 1105
1995 1270
1996 1206
1997 1119
1998 1154
1999 1173
2000 1223
2001 1315
2002 1290
2003 1356
2004 1460
2005 1436
2006 1345
2007 1430
2008 1278
2009 1316
2010 1391
2011 1585
2012 1462
2013 1428
2014 1394
2015 1199
2016 945
2017 747
2018 522
2019 212
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

37,469 results
Results by year
Filters applied: . Clear all
Page 1
Interferons α and β in cancer: therapeutic opportunities from new insights.
Borden EC. Nat Rev Drug Discov 2019 - Review. PMID 30679806
New insights into endogenous and exogenous activation of type I interferons in the tumour and its microenvironment have given impetus to drug discovery and patient evaluation of interferon-directed strategies. ...This Review discusses new interferon-directed therapeutic opportunities, ranging from cyclic dinucleotides to genome methylation inhibitors, angiogenesis inhibitors, chemoradiation, complexes with neoantigen-targeted monoclonal antibodies, combinations with other emerging therapeutic interventions and associations of interferon-stimulated gene expression with patient prognosis - all of which are strategies that have or will soon enter translational clinical evaluation....
New insights into endogenous and exogenous activation of type I interferons in the tumour and its microenvironment have given impetus …
Type I interferons in the pathogenesis and treatment of canine diseases.
Klotz D, et al. Vet Immunol Immunopathol 2017 - Review. PMID 28895871
Type I interferons (IFNs) such as IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω represent cytokines, which are deeply involved in the regulation and activation of innate and adaptive immune responses. They possess strong antiviral, antiproliferative, and immunomodulatory activities allowing their use in the therapy of different viral diseases, neoplasms, and immune-mediated disorders, respectively. ...
Type I interferons (IFNs) such as IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω represent cytokines, which are deeply involved in the regulat …
Interferons.
Mahajan BB and Kaur S. Indian J Dermatol Venereol Leprol 2015. PMID 25566899 Free article.
Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.
Marziniak M and Meuth S. Adv Ther 2014 - Review. PMID 25182864 Free PMC article.
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. ...
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and ove
The interferons and their use in condyloma acuminata.
Browder JF, et al. Ann Pharmacother 1992 - Review. PMID 1376628
Intralesional interferon exerts its antiviral effects on infected cells without causing damage to the surrounding tissue. In general, success rates with intralesional interferon alfa are comparable to traditional modalities. There is also evidence that interferon alfa might be particularly useful in the treatment of lesions that have failed to respond to other modalities....
Intralesional interferon exerts its antiviral effects on infected cells without causing damage to the surrounding tissue. In general, …
The clinical application of the interferons: a review. NSW Therapeutic Assessment Group.
Stuart-Harris RC, et al. Med J Aust 1992 - Review. PMID 1376397
DATA EXTRACTION: A position paper was drafted on behalf of the NSW Therapeutic Assessment Group (NSWTAG). This was circulated to clinicians identified as having a particular interest in the use of the interferons in major NSW teaching hospitals, for comment and amendment where necessary. CONCLUSIONS: Two forms of alpha interferon, interferon alfa-2b and interferon alfa-2a have been approved for use in Australia, interferon alfa-2b for use in the management of hairy cell leukaemia and condylomata acuminata and interferon alfa-2a for use in the management of hairy cell leukaemia and human immunodeficiency virus (HIV) related Kaposi's sarcoma. ...
DATA EXTRACTION: A position paper was drafted on behalf of the NSW Therapeutic Assessment Group (NSWTAG). This was circulated to clin …
Interferons: Success in anti-viral immunotherapy.
Lin FC and Young HA. Cytokine Growth Factor Rev 2014 - Review. PMID 25156421 Free PMC article.
The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the first lines of host defense against invading pathogens. ...Due to their ability to modulate immune responses, they have become attractive therapeutic options to control chronic virus infections. ...
The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the first lines of host defense again …
Repurposing of gamma interferon via inhalation delivery.
Smaldone GC. Adv Drug Deliv Rev 2018 - Review. PMID 29886069
Interferon-γ (IFN-γ), currently delivered as a subcutaneous injection for chronic granulomatous disease and osteopetrosis, is a cytokine that can stimulate macrophage function and inhibit fibrotic pathways. ...
Interferon-γ (IFN-γ), currently delivered as a subcutaneous injection for chronic granulomatous disease and osteopetrosis, is a cytok
37,469 results
Jump to page
Feedback